- Global Pharma News & Resources

Outlook on the Transplant Diagnostics Global Market to 2027 - Featuring Hologic, Illumina, Qiagen and Immucor Among Others -

DUBLIN--(BUSINESS WIRE)--The "Transplant Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to's offering.

Transplant Diagnostics Market is poised to register a CAGR of 7.8% during the forecast period (2022-2027).

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biomerieux SA
  • Bio-Rad Laboratories Inc.
  • CareDx
  • F Hoffman-La Roche AG
  • Hologic Inc.
  • Illumina Inc.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Immucor, Inc.
  • Omixon Ltd.
  • GenDx
  • BioGenuix

Key Market Trends

Solid Organ Transplant Segment is Expected to Hold a Major Share over the Forecast Period

The Solid organ transplant segment is expected to hold a major share over the forecast period. Solid-organ transplantation, which started as an experimental approach in the 20th century, is now considered a well-established and practical definitive treatment option for patients suffering from end-stage organ dysfunction. The majority of transplants are done for kidneys, followed by the liver.

According to the Health Resources & Services Administration in February 2022, there are over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant include Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period.

Moreover, rising funding for solid organ transplantation will further contribute the growth of the market studied over the forecast period. For instance, according to the National Institutes of Health (NIH) in June 2021, the funding for organ transplant research in 2018, 2019 and 2020 were USD 184 million, USD 191 million, and USD 208 million respectively. The rise in funding for solid organ transplant research will drive the growth of this segment further due to the rise in adoption of transplant diagnostics in the research.

Therefore, owing to the above mentioned factors, this segment growth is expected to drive over the forecast period.

North America is Expected to Hold a Major Share and Expected to Show the same Pace over the Forecast Period

North America is expected to hold a major share in the transplant diagnostics market and expected to continue same pace over the forecast period.

Countries, like the United States and Canada, are well-equipped with the funded organizations, infrastructure, and government participation in raising funds and awareness, to promote transplantation of organs for patients. For instance, according to the National Institute of Health in June 2021, the findings for the research in transplantation were USD 650 million, USD 733 million and USD 721 million in 2018, 2019 and 2020 respectively. The rise in funding in the transplantation research will therefore lead to increased utilization of transplant diagnostics, drive the growth of the market in this region.

In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have been taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

Rising initiatives from the key market players is expected to contribute the market growth further. These companies are advanced in marketing new products for faster diagnostics of diseases, before and after the transplants, which are well accepted by the private organizations and governments of the United States and Canada.

For instance, in March 2022, NephroSant, a biotechnology firm devoted to speeding the assessment of early kidney damage has recruited first patient in the Evaluation of QSant for Underlying Allograft Rejection (AQUA) study. Up to 2,000 people will be enrolled and observed for 24 months, during which time QSant testing and standard-of-care diagnostics will be used to look for evidence of acute rejection. This type of trials will further boost the market growth of transplant diagnostics in North America due to greater adoption of transplant diagnostic test.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Transplant Procedures

4.2.2 Technological Advancements in Transplant Diagnostics

4.2.3 Government and Private Collaboration into Funding Research of Target Diseases

4.3 Market Restraints

4.3.1 High Cost of Transplant

4.3.2 Insurance and Reimbursement Policies

4.3.3 Social and Ethical Issues Related to Organ Transplant

4.4 Porter's Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

5.1 By Technology

5.2 By Product

5.3 By Transplant Type

5.4 By Application

5.5 By Geography


6.1 Company Profiles


For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Sep-2022